Education
About Us
Working with TipRanks
Follow Us
Lipocine (LPCN)
NASDAQ:LPCN
LPCN Stock Chart & Stats
$2.92
-$0.05(-1.04%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.04%)
Day’s Range― - ―
52-Week Range$2.52 - $12.37
Previous CloseN/A
Volume16.76K
Average Volume (3M)69.37K
Market Cap
$49.97M
Enterprise Value$46.07M
Total Cash (Recent Filing)$15.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 05, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding5,551,931
10 Day Avg. Volume103,401
30 Day Avg. Volume69,372
Financial Highlights & Ratios
PEG Ratio-31.18
Price to Book (P/B)1.24
Price to Sales (P/S)2.33
P/FCF Ratio-19.87
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit21.07
Enterprise Value/Ebitda-7.37
Forecast
1Y Price Target
$10.88Price Target Upside272.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCompletion of patient enrollment and dosing in the Phase 3 pivotal trial positions the program for a topline readout and a potential U.S. regulatory submission if results are favorable.
Product DifferentiationAn oral at-home formulation that offers rapid relief compared with intravenous treatment could become a preferred option and address substantial unmet need in postpartum depression.
Safety ProfileA favorable safety profile in trials, with no drug discontinuations or drug-related serious adverse events reported, supports regulatory confidence and wider patient adoption.
Bears Say
Financing RiskPotential need to raise additional capital creates dilution risk and could put downward pressure on the stock if financing terms are unfavorable.
Lipocine News
LPCN FAQ
What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $2.52 and its highest was $12.37 in the past 12 months.
What is Lipocine’s market cap?
Lipocine’s market cap is $49.97M.
When is Lipocine’s upcoming earnings report date?
Lipocine’s upcoming earnings report date is Mar 05, 2026 which is in 31 days.
How were Lipocine’s earnings last quarter?
Lipocine released its earnings results on Nov 06, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.05.
Is Lipocine overvalued?
According to Wall Street analysts Lipocine’s price is currently Undervalued.
Does Lipocine pay dividends?
Lipocine does not currently pay dividends.
What is Lipocine’s EPS estimate?
Lipocine’s EPS estimate is -0.61.
How many shares outstanding does Lipocine have?
Lipocine has 5,551,931 shares outstanding.
What happened to Lipocine’s price movement after its last earnings report?
Lipocine reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Lipocine?
Currently, no hedge funds are holding shares in LPCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
LPCN Stock 12 Month Forecast
Average Price Target
$10.88
▲(272.43% Upside)
Technical Analysis
Ownership Overview
15.31%
Insiders
4.48% Mutual Funds
<0.01% Other Institutional Investors
76.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---